Research Article
Five-Year Assessment of Time of Sputum Smears Conversion and Outcome and Risk Factors of Tuberculosis Patients in Central Iran
Table 2
Impact of comorbidities and demographic, microbiological, and therapeutic variables on sputum smear conversion at the end of the intensive phase (
).
| Characteristic | | Sputum conversion status | value | | Conversion number (%) | Nonconversion number (%) |
| Sex | Male | 83 (83.8) | 16 (16.2) | 0.925 | Female | 75 (83.3) | 15 (16.7) |
| Age | ≤50 | 60 (80) | 15 (20) | 0.279 | >50 | 98 (86) | 16 (14) |
| Nationality | Iranian | 84 (85) | 15 (15) | 0.626 | Non-Iranian | 74 (82.2) | 16 (17.8) |
| Initial sputum grading | ≤2+ | 122 (88.4) | 16 (11.6) | 0.003 | 3+ | 35 (70) | 15 (30) |
| Accompanying disease | DM | 14 (70) | 6 (30) | 0.033 | Otherwise healthy (No comorbidity) | 136 (87.8) | 19 (12.2) |
| Treatment regimen | HRZE | 139 (83.7) | 27 (16.3) | 0.625 | HRZES* | 13 (86.7) | 2 (13.3) | HRE | 4 (66.7) | 2 (33.3) | HZE | 2 (100) | 0 (0) |
| Treatment category | CAT I | 144 (83.2) | 29 (16.8) | 0.660 | CAT II | 14 (87.5) | 2 (12.5) |
|
|
HRZES*: isoniazide, rifampicin, pyrazinamide, ethambutol, and streptomycin.
|